Subscribe To
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for […] The post Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application ap...
Read More
Posted: Dec 1 2022, 22:34
Author Name: forextv
Views: 110897